A study of CBA-1535 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug, CBA-1535, which is designed to help your immune system attack cancer cells. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor that has spread or cannot be removed, and standard treatments no longer work or are not an option for you.
- You should be able to take care of yourself (ECOG score 0 or 1).
- Your doctor expects you to live at least 3 more months.
- You must not have had other experimental drugs or antibody treatments (including immunotherapy) in the past 28 days, or regular cancer drugs in the past 14 days.
- You should not have had a severe allergic reaction to protein-based drugs (like therapeutic antibodies) in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CBA-1205 for people with advanced solid tumors, liver cancer, melanoma, or certain childhood cancers that have not responded to standard treatments. The drug targets a protein called DLK1 found on some cancer cells.
This trial tests a new drug called ABL103 combined with pembrolizumab (immunotherapy) and with or without a chemotherapy drug called taxane. It is for people with advanced or metastatic solid tumors that have stopped responding to standard treatments or cannot tolerate them.
This trial tests a new drug, BHV-1510, alone or combined with another drug (cemiplimab), for people with advanced solid tumors that haven't responded to other treatments. It's for those who are still in fairly good health and have not had certain prior treatments.
This trial tests a new drug, BHV-1530, either alone or with another drug called cemiplimab, for people with certain advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it's safe and effective.
This early-phase study tests a new treatment in people with advanced (locally advanced or metastatic) solid tumors that have worsened or cannot be treated with standard therapies. It may help shrink tumors or slow growth, and it also helps doctors learn the safest way to use the medicine.
This study tests a new drug, CRB-601-01, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and can help shrink tumors.
Hear when a new Refractory Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.